ABSTRACT

Objective: Optimal debulking in interval debulking surgery (IDS) after neoadjuvant chemotherapy (NAC) has been reported as a prognostic factor for patients with ovarian cancer. However, the identification of microscopic residual disease (MRD) using visualization and palpation is subjective. Peritoneal washing cytology (PWC) during IDS is an easy-to-implement, objective approach for assessing disease status, although its clinical relevance and association with MRD is not known. The aim of this study was to evaluate the efficacy of PWC during IDS.

Methods: In total, 164 patients diagnosed with ovarian cancer at our institution were retrospectively evaluated, including 64 who had received NAC. Seventeen patients had undergone an exploratory laparotomy followed by NAC, while the remaining patients were diagnosed based on imaging, peritoneal cytology, and tumor markers. The PWC was performed before intraperitoneal observation at laparotomy during IDS.

Results: NAC-treated patients had stage III–IV disease. IDS was performed in 78.1% of NAC-treated patients. Seventeen patients (26.6%) were PWC-negative and 33 patients (51.6%) were PWC-positive. Fourteen patients (21.9%) had progressive disease and were ineligible for IDS. The median overall survival of the PWC-negative, PWC-positive, and non-IDS groups was 47, 18, and 5 months, respectively. The differences were significant (p<0.01). PWC was an independent prognostic factor in the multivariate Cox regression analysis (p<0.001).

Conclusion: PWC during IDS may be a prognostic factor for NAC-treated patients with ovarian cancer. PWC may be more useful than visualization and palpation in IDS for determining the presence of MRD.

Keywords: Peritoneal Washing Cytology; Neoadjuvant Treatment; Interval Debulking Surgery; Ovarian Neoplasms; Prognosis; Overall Survival

INTRODUCTION

Neoadjuvant chemotherapy (NAC) followed by surgical cytoreduction is a feasible approach for patients with advanced ovarian cancer. Previous reports of retrospective and non-randomized prospective studies [1-4] have demonstrated non-inferior survival with reduced...
serious morbidity in NAC-treated patients. Overall survival (OS) inversely correlates with residual tumor size or residual disease (RD) after primary debulking surgery (PDS) [5]. Moreover, RD is a significant prognostic factor in NAC-treated patients [6]. There is no significant difference in survival between patients treated with NAC or PDS who underwent complete surgery (no RD). However, compared to PDS, NAC is associated with reduced OS in patients both with stage IIIC and RD with <1.0 cm residual tumor size (RD<1.0 cm) [7]. Onda and Yoshikawa [1] suggested that the definition of optimal debulking in interval debulking surgery (IDS) should be more stringent than in PDS.

Intraoperative surgical assessment with direct visualization and palpation is currently the standard procedure for evaluating RD in patients with ovarian cancer who have undergone PDS or IDS. Determination by visualization and palpation can be influenced by various factors (e.g., the surgeon’s experience, adequate evaluation of tumor sites, and surgeon and patient expectations) [8-11].

Peritoneal washing cytology (PWC) is an indicator of ovarian surface involvement and peritoneal dissemination in ovarian cancer. Therefore, PWC provides valuable information on staging and prognosis, as shown in clinical guidelines [12,13]. The PWC during IDS may overcome the limitations of micrographic evaluation of RD, which can be easily implemented into standard surgical procedures. Although one study by Nagasaka et al. [14] reported that PWC during IDS is associated with progression-free survival (PFS) in patients with advanced ovarian cancer, the efficacy of PWC during IDS and its effects on OS has not yet been determined. Therefore, the aim of this study was to evaluate the efficacy of PWC during IDS in relation to OS.

**MATERIALS AND METHODS**

1. **Patients and study design**
This study was conducted in accordance with the Declaration of Helsinki and the Reporting Recommendations for Tumor Marker Prognostic Studies of the National Cancer Institute. The retrospective design was approved by the Institutional Review Board of Kanagawa Cancer Center (Yokohama, Japan; 28-EKI-58). All study participants provided written informed consent. Patients with a diagnosis of primary ovarian cancer who were receiving treatment with NAC at our institution between January 1, 2011 and December 31, 2015 were identified. The median followed-up period for patients was 18.5 (0–67) months.

2. **Diagnosis and treatment**
An ovarian cancer diagnosis of adenocarcinoma was made by exploratory laparotomy (EL) or peritoneal cytology along with imaging findings and tumor markers. Patients who had received NAC at our institution, but had undergone an EL elsewhere, were included in this study. Patients with co-existing double primary cancers were excluded. Standard chemotherapy was administered as NAC followed by IDS. The chemotherapy regimens were primarily taxane- and platinum-based combinations. The baseline was the date of NAC initiation. The decision to perform IDS was made by the status of primary tumor and metastases as assessed with imaging and/or changes in serum cancer antigen 125 (CA125) levels. The patients who showed complete response or partial response, in accordance with the modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria, after NAC, underwent IDS as they were expected to achieve optimal cytoreductive surgery. Those who presented with a negative conversion or decreasing
levels of CA125 in response to NAC were also selected as IDS. Patients who had progressive disease were ineligible for IDS (non-IDS group).

Surgical procedures were performed to achieve optimal cytoreduction. At laparotomy for IDS, free abdominal fluid was aspirated, provided there were ascites in the Douglas’ pouch before intraperitoneal observation. In the absence of ascites, peritoneal washing of the Douglas’ pouch was performed with 50.0 mL of saline and the fluid was collected for PWC. Direct visualization and palpation of the peritoneum of the colon, intestine, diaphragm, and Douglas’ pouch was performed after washing and aspiration. The standard procedure for IDS in patients with ovarian cancer includes a total abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy, with debulking surgery performed to minimize the RD, if metastases were present. Completion of IDS indicates completion of the standard procedure for IDS. Pelvic and para-aortic lymph node dissection was not performed except for 2 patients who were clinically diagnosed with massive swelling of lymph nodes. Optimal cytoreduction was defined as no RD≥1.0 cm in the largest diameter at the completion of IDS.

Intraoperative complications were defined as urinary tract injury, neural injury, vascular injury, or bowel injury. Perioperative complications included thromboembolic disease, gastrointestinal/urinary anastomotic leaks, ileus, wound infections, wound dehiscence, fever on the third postoperative day or later, cystitis, atelectasis, unplanned return to the operating room, readmission, or death within 30 days of the initial surgery.

3. Statistical analyses

Patient demographic and clinical characteristics were compared using the \( \chi^2 \) test or Student’s t-test. Survival curves were plotted using the Kaplan-Meier method and compared using the log-rank test. Multivariate analyses were performed using a Cox proportional hazards model with stepwise selection. OS was measured from the date of NAC initiation to the date of death, with surviving patients censored at the date of last contact. PFS was measured from the date of initial diagnosis to the date of progression or death, whichever occurred first. Patients were followed on a regular basis using physical, serological, or radiological examinations, based on National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Ovarian Cancer IncludingFallopian Tube Cancer and Primary Peritoneal Cancer (version 2, 2013), and came to the hospital at times when they experienced symptoms. Progression of disease was diagnosed by contrast computed tomography (CT) or magnetic resonance imaging (MRI) using modified RECIST criteria (version 1.1). Patients were stratified into PWC-negative, PWC-positive, and non-IDS groups. Patients were also stratified according to serum CA125 levels of < or ≥75.0 IU/mL before IDS. Statistical differences were considered significant when the 2-sided p-value was less than 0.05. All statistical analyses were conducted using Statistical Package for the Social Sciences for Windows, software version 24.0 (IBM Corp., Armonk, NY, USA).

RESULTS

1. Patient demographic and clinical characteristics

In total, 164 patients diagnosed with ovarian cancer were analyzed in this study, including 64 patients who had received NAC. Among them, 17 patients (26.6%) who underwent an EL had biopsy proven ovarian cancer. The remaining 47 patients (73.4%) had cytology showing adenocarcinoma and CT findings consistent with primary ovarian cancer.
The demographic and clinical characteristics of the patients in the PWC-positive, PWC-negative, and non-IDS groups are summarized in Table 1. Patients treated with NAC had stage III–IV disease. In addition, IDS was performed in 78.1% of NAC-treated patients. Seventeen patients (26.6%) were PWC-negative and 33 patients (51.6%) were PWC-positive. Fourteen patients (21.9%) were in the non-IDS group. Fifty-nine of the 64 ovarian tumors were surface epithelial ovarian cancer. The demographic and clinical characteristics of the 3 groups did not differ significantly, except for histology.

### 2. Surgical parameters and complications

The perioperative parameters and postoperative complications of IDS in the PWC-negative and PWC-positive groups are shown in Table 2. The characteristics of the 2 groups did not differ significantly. Optimal debulking (RD<1.0 cm) was achieved in 72.0% of patients (n=36) and complete cytoreduction (no RD or without macroscopically residual tumors; RD=0) was achieved in 48.0% of patients (n=24). The largest RD was ≥2.0 cm in diameter.

### Table 1. Demographic and clinical characteristics of patients with ovarian cancer who had received NAC between 2011 and 2015

| Characteristic                  | All          | PWC-negative | PWC-positive | Non-IDS | p-value* |
|---------------------------------|--------------|--------------|--------------|---------|----------|
| Patients                        | 64           | 17 (26.6)    | 33 (51.6)    | 14 (21.9)| 0.499    |
| Age (yr)                        | 59.6±1.5     | 59.0±2.7     | 59.9±1.7     | 63.2±2.8|          |
| Histology                       |              |              |              |         | 0.016†   |
| Serous                          | 29 (45.3)    | 9 (52.9)     | 19 (57.6)    | 1 (7.1) |          |
| Clear cell                      | 8 (12.5)     | 0            | 6 (18.2)     | 2 (14.3)|          |
| Mucinous                        | 1 (1.6)      | 0            | 0            | 1 (7.1) |          |
| Endometrioid                    | 0            | 0            | 0            | 0       |          |
| Adenocarcinoma                  | 22 (34.4)    | 7 (41.2)     | 6 (18.2)     | 9 (64.3)|          |
| Other                           | 4 (6.3)      | 1 (5.9)      | 2 (6.1)      | 1 (7.1) |          |
| Stage III                       | 30           | 8            | 16           | 6       | 0.939    |
| Stage IV                        | 34           | 9            | 17           | 8       |          |
| CA125 level pre-NAC (IU/mL)     | 3,595±636    | 2,702±741    | 4,809±1,065  | 1,818±992| 0.169    |
| Taxane+platinum (%)             | 96.9         | 94.1         | 97.0         | 100     | 0.644    |
| NAC cycle                       | 5.6±0.192    | 5.47±0.298 (3–8) | 5.67±0.249 (3–11) | 5.36±1.386 (1–19)| 0.926    |
| EL                              | 19 (29.7)    | 7 (41.1)     | 8 (24.2)     | 4 (28.6)| 0.460    |

Data are shown as number (%) or mean±standard error (range).

CA125, cancer antigen 125; EL, exploratory laparotomy; IDS, interval debulking surgery; NAC, neoadjuvant chemotherapy; PWC, peritoneal washing cytology.

*One-way analysis of variance or Pearson's correlation coefficient; †p<0.05.

### Table 2. Perioperative parameters and postoperative complications of IDS following NAC in patients with positive and negative PWC

| Characteristic                  | PWC-negative (n=17) | PWC-positive (n=33) | p-value* |
|---------------------------------|---------------------|---------------------|----------|
| Completion of IDS               | 16 (94.1)           | 29 (87.9)           | 0.650    |
| RD status                       |                     |                     |          |
| 0                               | 11/17 (64.7)        | 13/33 (39.4)        | 0.136    |
| <1                              | 15/17 (88.2)        | 21/33 (63.6)        | 0.099    |
| ≥2                              | 1/17 (5.9)          | 11/33 (33.3)        | 0.039†   |
| Blood loss (mL)                 | 404.4±61.2          | 694.1±81.4          | 0.007†   |
| Blood transfusion               | 7 (41.2)            | 12 (36.4)           | 0.767    |
| Surgical time of IDS (min)      | 160.5±8.6           | 177.6±10.4          | 0.283    |
| Perioperative complications     | 3 (17.6)            | 1 (3.0)             | 0.273    |
| Death within 30 days of surgery | 0 (0.0)             | 0 (0.0)             |          |
| CA125 level pre-IDS (IU/mL)     | 23.7±4.9            | 267.1±127.8         | 0.066    |
| CA125 level pre-IDS (≥75 IU/mL) | 0 (0.0)             | 21 (63.6)           | 0.004†   |
| CA125 ratio                     | 0.03±0.08           | 0.12±0.06           | 0.088    |
| Interval between NAC and IDS (mo)| 4.8±0.7             | 4.6±0.3             | 0.777‡   |

Data are shown as number (%) or mean±standard error.

CA125, cancer antigen 125; IDS, interval debulking surgery; NAC, neoadjuvant chemotherapy; PWC, peritoneal washing cytology; RD, residual disease.

*Fisher’s exact test or Student’s t-test; †p<0.05; ‡Interval between the date of commencing NAC and the date of IDS.
in 24.0% of patients after IDS (n=12), and this was significantly associated with the PWC-positive group (p<0.05).

Intraoperative complications were not detected in patients who had undergone IDS. Postoperative complications in the PWC-negative group included a transient abnormality in hepatic function, a urinary tract infection, and an abscess that required surgery in 1 patient each. In the PWC-positive group, 1 patient experienced cholecystitis. Blood loss was significantly lower in the PWC-negative group than in the PWC-positive group (p<0.01).

3. Survival analyses
The median OS of patients in the PWC-negative, PWC-positive, and non-IDS groups was 47, 18, and 5 months, respectively (Fig. 1A). Significant differences were observed between the PWC-negative and PWC-positive (Mantel-Cox log-rank test, p<0.01), PWC-negative and non-IDS (p<0.001), and PWC-positive and non-IDS (p<0.001) groups. The median OS of patients in the IDS (PWC-negative and PWC-positive groups) and non-IDS groups was 27 and 5 months, respectively (p<0.001). The median PFS of patients in the PWC-negative, PWC-positive, and non-IDS groups was 17, 13, and 5 months, respectively (Fig. 1B). Significant

---

**Fig. 1.** Kaplan-Meier curves of (A) OS and (B) PFS in patients with ovarian cancer. Kaplan-Meier curves of OS in patients with (C) stage III and (D) stage IV disease. IDS, interval debulking surgery; NAC, neoadjuvant chemotherapy; OS, overall survival; PFS, progression-free survival; PWC, peritoneal washing cytology.
differences were observed between the PWC-negative and PWC-positive (p<0.01), PWC-negative and non-IDS (p<0.001), and PWC-positive and non-IDS (p<0.01) groups.

The PWC-positivity in IDS correlated with RD>2.0 cm (p<0.05), but not RD>1.0 cm (p>0.05) or RD=0 (p>0.05). Within the optimal debulking group (RD<1.0 cm), the median OS was 47 and 18 months for PWC-negative and PWC-positive patients, respectively (p<0.05) (Fig. 2A). Within the complete resection group (RD=0), the median OS was 55 and 29 months for PWC-negative and PWC-positive patients, respectively (p<0.05) (Fig. 2B). The median OS of patients with stage III (Fig. 1C) and stage IV (Fig. 1D) disease was 16.5 and 21 months, respectively. This difference was not significantly different. However, within each stage, a significant difference was observed between the PWC-negative, PWC-positive, and non-IDS groups.

The operative time for IDS was not significantly shorter in the PWC-negative group. However, the blood loss volume was significantly lower in this group (p<0.05).

4. Serum CA125 levels
The mean CA125 level pre-IDS (post-NAC) was 23.7 and 267 IU/mL in the PWC-negative and PWC-positive groups (p=0.066, Table 2). The CA125 ratio (pre-NAC / pre-IDS) of PWC-negative and PWC-positive patients was 0.03 and 0.12 (p>0.05, Table 2), respectively. The proportion of patients with ≥75.0 IU/mL pre-IDS serum CA125 level was 0% in the PWC-negative group and 55.3% in the PWC-positive group, respectively (p<0.01, Table 2). The median OS of patients in the <75.0 and ≥75.0 IU/mL pre-IDS serum CA125 groups was 45.3 and 18 months, respectively (p<0.001) (Fig. 3A). Univariate analyses showed associations with OS and PFS in terms of the pre-IDS serum CA125 level (≥75.0 IU/mL) (p=0.001 and p<0.01, respectively). In patients with pre-IDS serum CA125 levels of <75.0 IU/mL, the median OS was 53.5 and 35.5 months for the PWC-negative and PWC-positive groups, respectively (p<0.05) (Fig. 3B).

5. Multivariate analysis
In a multivariate Cox regression model, in patients who had received NAC; PWC-negative, and histology (serous adenocarcinoma) were identified as independent favorable predictors of OS. PWC-negative was also identified as an independent favorable predictor of PFS. The
hazard ratios for these variables are shown in Table 3. There were no significant differences in age, clinical stage, CA125 level pre-NAC, histology (clear cell carcinoma), NAC cycles (≤6), and the existence of EL.

In patients who had undergone IDS; PWC-negative, with RD<1.0 cm, histology (serous adenocarcinoma), and the number of NAC cycles (≤6) were identified as favorable independent predictors of OS. PWC-negative, having an RD<1.0 cm and the number of NAC cycles (≤6) were also identified as independent positive predictors of PFS. The hazard ratios for these variables are also shown in Table 3. There were no significant differences in age, clinical staging, the serum CA125 level pre-NAC or IDS, the ratio of CA125 level, the duration from starting NAC to IDS, the existence of EL, completion of IDS, blood volume in IDS, histology (clear cell carcinoma), RD=0, or RD≥2 cm.

**DISCUSSION**

In this study, we investigated the prognostic significance of PWC in NAC-treated patients with ovarian cancer. Optimal debulking in IDS after NAC has been reported to be a prognostic factor for patients with ovarian cancer [1,6,7].
The PWC-negative patients in IDS exhibited a dramatically improved OS compared to PWC-positive patients in the Kaplan-Meier analysis. The PWC is not only a useful indicator of clinical staging and prognostic information in PDS [12], but it can also serve as an independent predictor of OS for IDS. The multivariate Cox regression analysis in our study supports this hypothesis.

Many studies have demonstrated a higher efficacy of surgery when combined with NAC for IDS [1-4,7,15-17]. The 5-year survival rate of patients without RD after IDS was comparable to that of patients with minimal RD (RD<2.0 cm) after PDS, however, the 5-year survival rate of patients with minimal RD (RD<2.0 cm) after IDS is worse (0%) [15]. Onda et al. [16] suggested that the definition of optimal debulking in IDS should be no RD, despite the definition in PDS being RD<1.0 cm. This may be explained by the fact that the meaning of RD after PDS and IDS differs, as chemo-resistance may be altered by NAC [16]. In the present study, the median OS of patients in the debulking (RD<2.0 cm) and largest RD (RD≥2.0 cm) groups was 28.5 and 17 months, respectively (p<0.05) (Supplementary Fig. 1A), and the median OS of patients in the optimal debulking (RD<1.0 cm) and non-optimal debulking (RD≥1.0 cm) groups was 28.5 and 17 months, respectively (p<0.05) (Supplementary Fig. 1B), which showed that optimal debulking with RD<1.0 cm was associated with improved OS with statistically significant difference. Whereas, the median OS of patients in the no RD (complete cytoreduction; RD=0) and RD (incomplete cytoreduction; RD>0) groups was 27 and 20 months, respectively (p>0.05) (Supplementary Fig. 1C). This showed that complete cytoreduction did not improve OS because incomplete cytoreduction (RD>0) included optimal debulking with 0<residual tumor size<1 cm; and no significant difference in OS was observed between patients with no RD (RD=0) and those with minimal RD (0<RD<1.0 cm) in our study. The median OS of patients in the no RD (RD=0), RD 0<1, and RD>1.0 cm groups was 27, 31, and 17 months, respectively (Supplementary Fig. 1D). Thus, it is too difficult and subjective to identify microscopic peritoneal lesions, regardless of whether viable cancer cells are present or not. Microscopic lesions may remain due to inflammatory or fibrotic processes after NAC. PWC-positivity strongly correlated with large RD (RD>2.0 cm) in IDS, but did not correlate with minimal or no RD in our study. PWC may be more sensitive than macroscopic examinations to detect microscopic RD (MRD) which includes viable cancer cells, based on the positive association of PWC with reduced OS in patients who have undergone optimal debulking surgery (RD≤1.0 cm) and complete resection (RD=0) (Fig. 2). Therefore, PWC of the Douglas’ pouch could be an effective alternative evaluation method that may aid in overcoming the deficiencies in detecting MRD using visualization and palpitation. Interestingly, 13 patients who had undergone complete cytoreduction (39.4%) were PWC-positive. This suggests that residual cancer cells may remain microscopically present in the peritoneum [14]. Four patients with RD 0<residual tumor size<1 cm were PWC-negative. This may be the result of inflammatory or fibrotic processes after NAC treatment or a reduction in cancer cell migration activity. However, additional research is needed to identify the relationship between PWC and the activity of viable cancer cells.

Favorable associations have been detected between survival and the extent of decline in serum CA125 levels after PDS for advanced-stage ovarian cancer [11], and the value of serum CA125 levels of <75.0 IU/mL after the third NAC-cycle is an independent predictor of complete IDS [17]. In our study, pre-IDS serum CA125 levels (<75.0 IU/mL) were not only a predictive factor of OS and PFS, but also demonstrated a significant association with PWC status (Fig. 3A and Table 2). Among patients with pre-IDS serum CA125 levels of <75.0 IU/mL, the PWC-negative group exhibited a longer survival; the median OS was 53.5 and 35.5 months for the PWC-
negative and PWC-positive groups in patients with pre-IDS serum CA125 levels of <75.0 IU/mL, respectively (p<0.05) (Fig. 3B). Therefore, PWC status may be a predictive prognostic factor, along with pre-IDS serum CA125 level, for patients with ovarian cancer.

The median OS of patients with serous adenocarcinoma and clear cell carcinoma was 27 and 14 months, respectively (p<0.001) (Supplementary Fig. 2A), which showed that patients with serous adenocarcinoma exhibited a good prognosis, while those with clear cell carcinoma exhibited a significantly poorer prognosis. Despite PWC-positivity, the median OS was longer in patients with serous adenocarcinoma; the median OS was 36.5 and 19.3 months for patients with serous adenocarcinoma and non-serous adenocarcinoma within the PWC-positive group, respectively (p<0.05) (Supplementary Fig. 2B). All clear cell carcinoma patients were PWC-positive, demonstrating that clear cell carcinoma is chemoresistant [1]. Therefore, NAC may not benefit patients with a chemoresistant histology very well, and another regimen of NAC may be needed especially for patients with clear cell carcinoma.

Within the IDS group (PWC-negative and PWC-positive patients), the median OS was 46 and 16 months for patients who had received ≤6 or >6 cycles of NAC, respectively (p<0.05) (Supplementary Fig. 3). As more cycles are needed to treat patients who are less responsive to NAC, it is feasible that a small number of NAC cycles (n≤6) may be a positive prognostic factor.

The limitations of this study include its retrospective single-center study design. Therefore, a large-scale prospective trial to justify the efficacy of PWC during IDS is warranted.

In conclusion, our study suggests that PWC during IDS may be a prognostic factor for NAC-treated patients with ovarian cancer, specifically for MRD. The PWC may aid in overcoming the difficulty in determining the presence of MRD using visualization and palpation. We propose that PWC should be included in the intraoperative evaluation of IDS.

ACKNOWLEDGMENTS

We would like to thank Sachiko Kaminishizono, MD, and Mariko Ikeda, MD for their assistance with data collection and patient care. We would also like to thank Editage (www.editage.jp) for English language editing.

SUPPLEMENTARY MATERIALS

Supplementary Fig. 1
(A) The median OS of patients in the debulking (RD<2.0 cm) and largest RD (RD≥2.0 cm) groups was 28.5 and 17 months, respectively (p<0.05). (B) The median OS of patients in the optimal debulking (RD<1.0 cm) and non-optimal debulking (RD≥1.0 cm) groups was 28.5 and 17 months, respectively (p<0.05). (C) The median OS of patients in the no RD (complete cytoreduction, no RD without macroscopically residual tumors; RD=0) and RD (incomplete cytoreduction including optimal and non-optimal; RD>0) groups was 27 and 20 months, respectively (p<0.05). (D) The median OS of patients in the no RD (RD=0), RD 0–1, and RD>1.0 cm groups was 27, 31, and 17 months, respectively.

Click here to view
Supplementary Fig. 2
Kaplan-Meier curves of OS according to histological type. (A) Serous adenocarcinoma vs. clear cell carcinoma and (B) serous adenocarcinoma vs. non-serous adenocarcinoma in patients with positive PWC.

Click here to view

Supplementary Fig. 3
Kaplan-Meier curves of OS in patients with PWC-negative and PWC-positive patients in the IDS group, the median OS was 46 and 16 months for patients who had received ≤6 or >6 cycles of NAC, respectively.

Click here to view

REFERENCES

1. Onda T, Yoshikawa H. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions. Expert Rev Anticancer Ther 2011;11:1053-67. [PUBMED] [CROSSREF]

2. Kuhn W, Rutke S, Späthe K, Schmalfeldt B, Florack G, von Hundelshausen B, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 2001;92:2585-91. [PUBMED] [CROSSREF]

3. Hegazy MA, Hegazi RA, Elshafei MA, Setit AE, Elshamy MR, Elattoongy M, et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J Surg Oncol 2005;3:57. [PUBMED] [CROSSREF]

4. Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for primary surgery. J Obstet Gynaecol Res 2006;32:99-106. [PUBMED] [CROSSREF]

5. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4. [PUBMED]

6. Colombo PE, Mourregot A, Fabbro M, Gutowski M, Saint-Aubert B, Quenet F, et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol 2009;35:135-43. [PUBMED] [CROSSREF]

7. Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, et al. Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. J Clin Oncol 2016;34:3854-63. [PUBMED]

8. Sala E, Mannelli L, Yamamoto K, Griffin M, Griffin N, Grant L, et al. The value of postoperative/preadjuvant chemotherapy computed tomography in the management of patients with ovarian cancer. Int J Gynecol Cancer 2011;21:296-301. [PUBMED]

9. Préfontaine M, Gelfand AT, Donovan JT, Powell JL. Reproducibility of tumor measurements in ovarian cancer: a study of interobserver variability. Gynecol Oncol 1994;55:87-90. [PUBMED] [CROSSREF]

10. Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 2006;100:33-7. [PUBMED] [CROSSREF]

11. Zwakman N, van de Laar R, Van Gorp T, Zusterzeel PL, Snijders MP, Ferreira I, et al. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer. J Gynecol Oncol 2017;28:e7. [PUBMED] [CROSSREF]
12. Shield P. Peritoneal washing cytology. Cytopathology 2004;15:131-41.

13. Davidson W, Madan R, O’Neil M, Tawfik OW, Fan F. Utility of peritoneal washing cytology in staging and prognosis of ovarian and fallopian tube neoplasms: a 10-year retrospective analysis. Ann Diagn Pathol 2016;22:54-7.

14. Nagasaka K, Kawana K, Tomio K, Tsuruga T, Mori-Uchino M, Miura S, et al. Positive peritoneal cytology at interval surgery is a poor prognostic factor in patients with stage T3c advanced ovarian carcinoma: a retrospective study. J Obstet Gynaecol Res 2015;41:755-62.

15. Onda T, Yoshikawa H, Yasugi T, Matsumoto K, Taketani Y. The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment. Jpn J Clin Oncol 2010;40:36-41.

16. Onda T, Kobayashi H, Nakanishi T, Hatae M, Iwasaka T, Konishi I, et al. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecol Oncol 2009;113:57-62.

17. Pelissier A, Bonneau C, Chéreau E, de La Motte Rouge T, Fourchotte V, Darai E, et al. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol 2014;135:542-6.